Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.
Document Type
Article
Publication Date
1-2020
Keywords
JGM
JAX Source
J Clin Oncol 2020 Jan; 38:81-99
Volume
38
Issue
1
First Page
81
Last Page
99
ISSN
1527-7755
PMID
31743054
DOI
https://doi.org/10.1200/JCO.19.00367
Abstract
PURPOSE: Precision medicine trials in glioblastoma (GBM) are often conducted at tumor recurrence. However, second surgeries for recurrent GBM are not routinely performed, and therefore, molecular data for trial inclusion are predominantly derived from the primary sample. This study aims to establish whether molecular targets change during tumor progression and, if so, whether this affects precision medicine trial design.
MATERIALS AND METHODS: We collected 186 pairs of primary-recurrent GBM samples from patients receiving chemoradiotherapy with temozolomide and sequenced approximately 300 cancer genes.
RESULTS: The molecular profile of our cohort was identical to that of other GBM cohorts (
CONCLUSION: This large cohort of matched primary and recurrent
Recommended Citation
Draaisma K,
Chatzipli A,
Taphoorn M,
Kerkhof M,
Weyerbrock A,
Sanson M,
Hoeben A,
Lukacova S,
Lombardi G,
Leenstra S,
Hanse M,
Fleischeuer R,
Watts C,
McAbee J,
Angelopoulos N,
Gorlia T,
Golfinopoulos V,
Kros J,
Verhaak R,
Bours V,
van den Bent M,
McDermott U,
Robe P,
French P.
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol 2020 Jan; 38:81-99